Tislelizumab for relapsed/refractory peripheral T-cell lymphomas

For more information about this resource, please submit a medical information request.

Tislelizumab (BGB-A317) for relapsed/refractory peripheral T-cell lymphomas: safety and efficacy results from a phase 2 study